Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity

Liudmila Mus, Francesca Siani, Claudio Giuliano, Christina Ghezzi, Silvia Cerri, Fabio Blandini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

GBA1 gene encodes for the lysosomal membrane protein glucocerebrosidase (GCase). GBA1 heterozygous mutations profoundly impair GCase activity and are currently recognized as an important risk factor for the development of Parkinson's disease (PD). Deficits in lysosomal degradation pathways may contribute to pathological α-synuclein accumulation, thereby favoring dopaminergic neuron degeneration and associated microglial activation. However, the precise mechanisms by which GCase deficiency may influence PD onset and progression remain unclear. In this work we used conduritol-β-epoxide (CBE), a potent inhibitor of GCase, to induce a partial, systemic defect of GCase activity comparable to that associated with heterozygous GBA1 mutations, in mice. Chronic (28 days) administration of CBE (50 mg/kg, i.p.) was combined with administration of a classic PD-like inducing neurotoxin, such as MPTP (30 mg/kg, i.p. for 5 days). The aim was to investigate whether a pre-existing GCase defect may influence the effects of MPTP in terms of nigrostriatal damage, microglia activation and α-synuclein accumulation. Pre-treatment with CBE had tendency to enhance MPTP-induced neurodegeneration in striatum and caused significant increase of total α-synuclein expression in substantia nigra. Microglia was remarkably activated by CBE alone, without further increases when combined with MPTP. Overall, we propose this model as an additional tool to study pathophysiological processes of PD in the presence of GCase defects.

Original languageEnglish
Pages (from-to)289-296
Number of pages8
JournalNeurobiology of Disease
Volume124
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Glucosylceramidase
Parkinson Disease
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Synucleins
Microglia
Lysosome-Associated Membrane Glycoproteins
Gaucher Disease
Nerve Degeneration
Mutation
Dopaminergic Neurons
Neurotoxins
Substantia Nigra
Disease Progression
Genes

Keywords

  • CBE
  • Glucocerebrosidase
  • Mouse model
  • MPTP
  • Parkinson's disease
  • α-Synuclein

ASJC Scopus subject areas

  • Neurology

Cite this

@article{fe5e7905ba04432087cc5021f0df9aef,
title = "Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity",
abstract = "GBA1 gene encodes for the lysosomal membrane protein glucocerebrosidase (GCase). GBA1 heterozygous mutations profoundly impair GCase activity and are currently recognized as an important risk factor for the development of Parkinson's disease (PD). Deficits in lysosomal degradation pathways may contribute to pathological α-synuclein accumulation, thereby favoring dopaminergic neuron degeneration and associated microglial activation. However, the precise mechanisms by which GCase deficiency may influence PD onset and progression remain unclear. In this work we used conduritol-β-epoxide (CBE), a potent inhibitor of GCase, to induce a partial, systemic defect of GCase activity comparable to that associated with heterozygous GBA1 mutations, in mice. Chronic (28 days) administration of CBE (50 mg/kg, i.p.) was combined with administration of a classic PD-like inducing neurotoxin, such as MPTP (30 mg/kg, i.p. for 5 days). The aim was to investigate whether a pre-existing GCase defect may influence the effects of MPTP in terms of nigrostriatal damage, microglia activation and α-synuclein accumulation. Pre-treatment with CBE had tendency to enhance MPTP-induced neurodegeneration in striatum and caused significant increase of total α-synuclein expression in substantia nigra. Microglia was remarkably activated by CBE alone, without further increases when combined with MPTP. Overall, we propose this model as an additional tool to study pathophysiological processes of PD in the presence of GCase defects.",
keywords = "CBE, Glucocerebrosidase, Mouse model, MPTP, Parkinson's disease, α-Synuclein",
author = "Liudmila Mus and Francesca Siani and Claudio Giuliano and Christina Ghezzi and Silvia Cerri and Fabio Blandini",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.nbd.2018.12.001",
language = "English",
volume = "124",
pages = "289--296",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity

AU - Mus, Liudmila

AU - Siani, Francesca

AU - Giuliano, Claudio

AU - Ghezzi, Christina

AU - Cerri, Silvia

AU - Blandini, Fabio

PY - 2019/4/1

Y1 - 2019/4/1

N2 - GBA1 gene encodes for the lysosomal membrane protein glucocerebrosidase (GCase). GBA1 heterozygous mutations profoundly impair GCase activity and are currently recognized as an important risk factor for the development of Parkinson's disease (PD). Deficits in lysosomal degradation pathways may contribute to pathological α-synuclein accumulation, thereby favoring dopaminergic neuron degeneration and associated microglial activation. However, the precise mechanisms by which GCase deficiency may influence PD onset and progression remain unclear. In this work we used conduritol-β-epoxide (CBE), a potent inhibitor of GCase, to induce a partial, systemic defect of GCase activity comparable to that associated with heterozygous GBA1 mutations, in mice. Chronic (28 days) administration of CBE (50 mg/kg, i.p.) was combined with administration of a classic PD-like inducing neurotoxin, such as MPTP (30 mg/kg, i.p. for 5 days). The aim was to investigate whether a pre-existing GCase defect may influence the effects of MPTP in terms of nigrostriatal damage, microglia activation and α-synuclein accumulation. Pre-treatment with CBE had tendency to enhance MPTP-induced neurodegeneration in striatum and caused significant increase of total α-synuclein expression in substantia nigra. Microglia was remarkably activated by CBE alone, without further increases when combined with MPTP. Overall, we propose this model as an additional tool to study pathophysiological processes of PD in the presence of GCase defects.

AB - GBA1 gene encodes for the lysosomal membrane protein glucocerebrosidase (GCase). GBA1 heterozygous mutations profoundly impair GCase activity and are currently recognized as an important risk factor for the development of Parkinson's disease (PD). Deficits in lysosomal degradation pathways may contribute to pathological α-synuclein accumulation, thereby favoring dopaminergic neuron degeneration and associated microglial activation. However, the precise mechanisms by which GCase deficiency may influence PD onset and progression remain unclear. In this work we used conduritol-β-epoxide (CBE), a potent inhibitor of GCase, to induce a partial, systemic defect of GCase activity comparable to that associated with heterozygous GBA1 mutations, in mice. Chronic (28 days) administration of CBE (50 mg/kg, i.p.) was combined with administration of a classic PD-like inducing neurotoxin, such as MPTP (30 mg/kg, i.p. for 5 days). The aim was to investigate whether a pre-existing GCase defect may influence the effects of MPTP in terms of nigrostriatal damage, microglia activation and α-synuclein accumulation. Pre-treatment with CBE had tendency to enhance MPTP-induced neurodegeneration in striatum and caused significant increase of total α-synuclein expression in substantia nigra. Microglia was remarkably activated by CBE alone, without further increases when combined with MPTP. Overall, we propose this model as an additional tool to study pathophysiological processes of PD in the presence of GCase defects.

KW - CBE

KW - Glucocerebrosidase

KW - Mouse model

KW - MPTP

KW - Parkinson's disease

KW - α-Synuclein

UR - http://www.scopus.com/inward/record.url?scp=85058019971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058019971&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2018.12.001

DO - 10.1016/j.nbd.2018.12.001

M3 - Article

VL - 124

SP - 289

EP - 296

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -